IMPORTANCE Despite the increasing use of anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcomes remain unclear, with many patients requiring surgical intervention despite optimal medical management.
M edical therapies for inflammatory bowel diseases continue to evolve, but surgical interventions maintain a significant role, particularly in ulcerative colitis (UC). The clinical course of UC exhibits a highly variable spectrum of severity among patients. Approximately 50% of patients with chronic disease will relapse each year, and up to 90% of these patients will experience at least 1 relapse in 25 years. [1] [2] [3] Even with optimal medical management, approximately one-third of patients with UC requiring hospitalization for their disease will ultimately undergo surgery. 1, 4 Most of these patients experience either insufficient responses to medical therapy or intolerable adverse effects from medications. 5 The first class of biologic agents used in the treatment of inflammatory bowel diseases comprised antibodies targeting tumor necrosis factor (TNF), a pro-inflammatory cytokine. Infliximab first gained US Food and Drug Administration approval for the treatment of UC in 2005 and was followed several years later by adalimumab. [3] [4] [5] By interfering with the inflammatory cascade, anti-TNF agents have demonstrated improved mucosal healing, reductions in corticosteroid requirements, and induction or maintenance of remission. 2 However, because these underlying inflammatory mechanisms are also implicated in wound healing and infection defense, impairing these mechanisms in a surgical patient is justly met with some caution. Initially, approval of infliximab for UC was limited to patients with moderate to severe disease. Although described more thoroughly within the Crohn disease literature, a "topdown" approach, which employs early use of biologic agents to induce remission and is followed by maintenance with immunomodulators, has received increased emphasis. 6 This approach has also been used in patients with UC, and it has been suggested that a subgroup of patients with UC may benefit from this strategy. 6, 7 Furthermore, the indications for anti-TNF therapy have expanded to include salvage therapy for corticosteroid-resistant cases, decreasing the emergency colectomy rate to 29%. 8 Although improved, the colectomy population still represents a substantial proportion of patients undergoing surgery after a recent anti-TNF administration. The once-distinct indications for surgical and medical therapy are increasingly converging, and the patients who are now candidates for anti-TNF agents are the same ones who remain at high risk for surgery. Understanding the potential effect of administering anti-TNF agents on the surgical patient is therefore critical. In this study, we used a large national claims database to explore the effects of anti-TNF agents on surgical patients with UC.
Methods

Data
Between February 1, 2015, and June 2, 2016, we used the MarketScan Commercial Claims and Encounters (CCAE) database (Truven Health Analytics) to identify the patient cohort for this study. The CCAE database captures both inpatient and outpatient claims, including outpatient pharmaceutical claims, for patients (as well as their spouses and dependents) with employer-based private insurance in the United States. 9 Because it is based on insurance enrollment, the database contains information that has a strong longitudinal integrity throughout inpatient and outpatient encounters. The inclusion of both inpatient and outpatient pharmaceutical data, including prescription fills, provides an accurate reflection of patient medication utilization patterns and is a large advantage of this database. This study was approved by the institutional review board of the Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. The need for patient informed consent was waived for this study by the institutional review board of the Penn State Milton S. Hershey Medical Center because of the minimal risk of this study.
Patient Selection
A total of 2476 patients 18 years or older were identified through the CCAE database. These patients had inpatient and/or outpatient claims from January 6 , 556.8, and 556.9) were used to isolate patients with a UC diagnosis for inclusion in this study. If multiple admissions involving a surgical procedure were identified, then only data regarding the first surgical admission within the time frame were abstracted to identify the index UC-related procedure for each patient. Patients were excluded if they had a secondary ICD-9-CM diagnosis code for Crohn disease or if they were not continuously enrolled in an insurance plan for at least 180 days before and after the index surgery.
Key Points
Question Are adverse postoperative events higher among patients with ulcerative colitis who require anti-tumor necrosis factor (TNF) therapy?
Findings In this analysis involving the insurance claims records of 2476 patients who underwent colectomy or total proctocolectomy for ulcerative colitis, preoperative anti-TNF agent use was not associated with a significant increase in postoperative complications. However, anti-TNF agent use within 90 days of surgery among patients who underwent ileal pouch-anal anastomosis was associated with higher complication rates.
Meaning For patients using anti-TNF therapy for ulcerative colitis, avoidance of ileal pouch-anal anastomosis during the initial ulcerative colitis-associated procedure may be warranted.
Covariates
Preoperative comorbidities were identified with claims within 180 days prior to surgery using the Quan modification of the Charlson Comorbidity Index, which is based on 17 comorbidities. 10 Additional comorbidities were identified using ICD-9-CM diagnosis codes for various types of proteincalorie malnutrition (260.X, 261.X, 262.X, and 263.X) and for failure to thrive (783.2 and 783.7). Use of anti-TNF agents, corticosteroids, and immunomodulators within 90 days of surgery was identified using Healthcare Common Procedure Coding System codes for inpatient and outpatient claims and using generic names for outpatient pharmaceutical claims. Anti-TNF agents were adalimumab (J0135), certolizumab pegol (J0717), and infliximab (J1745). Corticosteroids were prednisone (J7506); hydrocortisone acetate, hydrocortisone sodium phosphate, and hydrocortisone sodium succinate (J1700, J1710, and J1720); and methylprednisolone, methylprednisolone acetate, and methylprednisolone sodium succinate (J1020, J1030, J1040, J2920, J2930, and J7509). Immunomodulators were azathioprine sodium (J7500, J7501), 6-mercaptopurine (S0108), and cyclosporine (J7502, J7515, and J7516). For patients with anti-TNF agent use, the most recent day prior to surgery when there was a claim for a biologic agent was collected. Emergency cases were defined as those with a claim for an emergency department (ED) visit within 2 days of the surgical procedure.
Outcomes
Primary outcomes of interest within each surgical group included complications, postoperative ED visits, and readmissions. Complications were defined according to the description by Loftus and colleagues 11 of postoperative complications relevant to patients with UC undergoing colorectal resections. These complications were identified from inpatient and outpatient claims with CPT or ICD-9-CM codes within 90 days of discharge; they included fistula, abscess, stricture, sepsispneumonia-bacteremia, wound debridement or dehiscence, anal/rectal repair or manipulation, lysis of adhesions, and revision of ileostomy. Postoperative ED visits were defined as a service subcategory code of 20 for inpatient and outpatient claims. Readmissions were defined as any inpatient claim within 90 days of discharge. Among patients receiving biologic agents, we examined whether receiving an infusion closer to the date of the index surgery affected postsurgical outcomes.
Statistical Analysis
Wilcoxon and χ 2 tests, as appropriate, were used to compare preoperative variables and postoperative outcomes between patients receiving and patients not receiving anti-TNF agents in each surgical group. Multivariable logistic regression was used to model the occurrence of each outcome within 90 days by the following covariates: anti-TNF agent use, age, sex, comorbidity index, malnutrition, failure to thrive, corticosteroid use, immunomodulator use, emergency case, and presence of diverting stoma (among the IPAA cohort only). A linear association for comorbidity index was assumed. Nonlinear associations (on the log-odds scale) for age were examined in these models using B-splines, but linear associations were found to be appropriate in all cases and were used in the final models. Odds ratios (ORs) and 95% CIs were reported for all factors in the models. P < .05 was considered statistically significant, and 2-sided P values were used. Among the subset of patients who received anti-TNF therapy, we examined whether outcomes differed according to time between anti-TNF agent use and surgery. Univariable logistic regression was used to model the occurrence of each outcome as a function of time since infusion. Nonlinear curves for day were tested using B-splines, but all nonlinear curves were nonsignificant, and thus linear curves were fit. The estimated probabilities of each outcome as a function of time were reported for these models. Multivariable analyses could not be performed because the event rates of each outcome were too small.
In addition, sensitivity analysis that excluded patients undergoing emergency surgery was performed given the inherent heterogeneity in disease severity and operative complexity in this population. All logistic models were refit after these exclusions.
Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute Inc) and R software, version 3.1.2 (http://www.r-project.org).
Results
Of the 2476 patients identified, 1379 (55.7%) were men and 1097 (44.3%) were women. The mean (SD) age of all patients was 42.1 (12.9) years.
Subtotal Colectomy or Total Abdominal Colectomy
A total of 950 patients (38.4%) who underwent an STC/TAC procedure were identified (Table 1) , of whom 254 (26.7%) had claims for an anti-TNF agent-primarily infliximab ( In univariate analyses, patients receiving anti-TNF agents compared with those with no anti-TNF agent use had fewer ED visits within 90 days of surgery (79 [31.1%] vs 270 [38.8%]; P = .03), but there were no differences in readmissions or complications. On multivariable analyses, however, the receipt of therapy was not significantly associated with these outcomes ( Table 3) . Among patients who received a biologic agent, the timing of its most recent administration did not influence the occurrence of any adverse outcomes within 90 days (Figure, A) .
Association of Anti-TNF Therapy With Postoperative Events in Ulcerative Colitis
Original (Table 3) . No associations were found between the timing of preoperative anti-TNF administration prior to the index surgery and occurrence of adverse postoperative outcomes within 90 days (Figure, B) .
Ileal Pouch-Anal Anastomosis
A total of 1172 patients (47.3%) who underwent IPAA as their index UC-related procedure were identified ( Table 1) . As in the other 2 cohorts, 303 patients (25.9%) in the IPAA cohort received anti-TNF agents, most of which was infliximab (Table 2) given at a mean (SD) of 46. 95% CI, 1.05-1.82). Because of this significant association, further analysis was performed to identify the specific complications responsible for this association ( Table 4) . Timing of anti-TNF therapy up to 90 days prior to the index surgery did not appear to influence the complication rate (Figure, C) .
Sensitivity Analysis
To test the robustness of these findings, a sensitivity analysis was performed that excluded all emergency cases in all logistic models. The estimated ORs from these models were similar to the estimates when using all patients for the 3 surgical groups and the 3 adverse postoperative outcomes.
Discussion
In the current literature, significant heterogeneity has been reported regarding the effects of anti-TNF agents on surgical patients with UC. Existing data are primarily based on retrospective studies, which vary by the types of surgery included (resections vs IPAA-related procedures) and the biologic agents studied (infliximab alone vs with adalimumab and certolizumab) and are often limited by small sample sizes. 
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In this study, only patients in the IPAA cohort demonstrated an increase in 90-day complications after preoperative use of anti-TNF agents. A sensitivity analysis removing any patients who had an ED visit within 2 days of admission corroborated this finding. This finding has been observed in several other studies, all of which included only patients undergoing IPAA-related procedures. 2, 21, 22 Of the 3 studies that also exclusively examined patients who underwent IPAA procedures but did not identify increases in complications, the anti-TNF arms had relatively small sample sizes of fewer than 30 patients and may not have been powered adequately to detect differences in complication rates. 4, 16, 20 In this study, as opposed to having an effect on restorative procedures, anti-TNF agents had no detrimental effect on postoperative complications in patients who underwent resection (STC/TAC or TPC/EI) as their initial UC-related surgery. Previous studies that examined patients undergoing only resection are sparse, with only a few studies examining patients undergoing only colectomy. 19, 32 Rather, many studies include mixed cohorts of patients undergoing both resection only and resection with IPAA. Of these studies, none identified an increased risk of postoperative complications in patients on preoperative anti-TNF therapy. [12] [13] [14] [15] [16] [17] [18] [19] A retrospective study by Gu and colleagues, 33 which stratified patients into those undergoing total proctocolectomy with IPAA vs subtotal colectomy, found increased rates of pelvic sepsis among patients who underwent IPAA and were receiving biologic therapy but no increased complications among patients who underwent colectomy and were receiving biologic therapy, which are consistent with our current findings. Considering mixed groups of surgical patients may, therefore, be diluting a detrimental effect of biologic agents on patients who underwent IPAA and was an observation suggested in a meta-analysis by Selvaggi and colleagues.
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Given the complexity of IPAA procedures, it is not surprising that this cohort appears more vulnerable to alterations in the inflammatory cascade induced by anti-TNF agents. The complications that either met or approached statistical significance between the groups included those associated with wound debridement or dehiscence or adhesion formation. This profile of complications suggests that these alterations in the inflammatory process may affect wound healing, although further studies focusing on this association are warranted. Although data on infliximab use in surgical patients with UC are conflicted, data on other anti-TNF agents in this population are largely absent. Of those that do include adalimumab and certolizumab, a variable effect of anti-TNF agents on postoperative complications was noted, similar to studies examining infliximab alone. 14, 15, 33 One study performed a subgroup analysis directly comparing complications between infliximab and adalimumab users and found no differences between the agents. 17 As the oldest biologic agent, infliximab offers the largest clinical experience and body of supporting literature but requires in-office intravenous infusion, unlike the subcutaneous self-administration permitted by adalimumab and certolizumab. 34 Furthermore, because various clinical considerations and emerging resistance patterns are used to guide the choice of biologic agents, an improved understanding of any differences between these 3 agents in a surgical population is an important area for future research. Several other significant associations identified in this study are consistent with previous findings in the literature. Female sex was associated with increased odds of all 3 adverse outcomes among patients in the IPAA group and with increased postoperative complications among patients in the STC/TAC group. A large retrospective study by Riegler and colleagues 35 noted an association of female sex and increased disease activity with greater colitis extent. Conversely, increasing age was associated with reduced disease severity in that study; in our study, older patients in the STC/ TAC cohort were found to have decreased odds of ED visits and readmissions. Interestingly, corticosteroid use was not found to be associated with postoperative complications after controlling for other patient covariates. The use of certain medications (eg, corticosteroids and immunomodulators) in this study was considered binary because dosages could not always be identified within the CCAE database. This limitation may have biased our results either toward the null hypothesis (by overestimating the effect of corticosteroids in patients who received only 1 dose) or toward showing a significant difference if the corticosteroid dosages used among anti-TNF patients were substantially higher than among patients not receiving anti-TNF therapy.
Limitations
Several limitations are present in this study. First, using the CCAE database, we were unable to determine whether patients had received inpatient infusions of anti-TNF agents preoperatively, thus potentially misclassifying some of the patients receiving anti-TNF agents and biasing the results toward the null hypothesis. Second, the CCAE database contains only privately insured patients and thus does not include the Medicare population (all patients 65 years or older), the Medicaid population, or individuals without health insurance. Although this proportion still represents most patients with UC, this subset is still not generalizable to the entire UC population because a previous study estimated that only 58% of patients with UC have continuous enrollment in a private health insurance plan for at least 1 year. 36 Third, although anastomotic leaks lack a specific ICD-9-CM code, they are commonly associated with intra-abdominal abscesses, which are captured by the definition of complications by Loftus and colleagues. 11 Finally, because only the initial procedure that patients underwent was captured in this analysis, we were unable to compare patients undergoing delayed completion proctectomy with IPAA with patients undergoing TPC with primary IPAA.
Conclusions
Postoperative complications were not increased among patients with UC receiving preoperative anti-TNF agents who underwent resection alone (STC/TAC or TPC/EI). Among patients undergoing a restorative procedure as their index UCrelated procedure, however, the use of anti-TNF therapy within 90 days of surgery was associated with increased complications. Therefore, in a patient who is a candidate for a restorative procedure, our data suggest that performing a TPC with concurrent IPAA as the initial UC-related procedure should be avoided or at least delayed for more than 90 days after anti-TNF agent use. It remains unclear whether a 3-stage or a modified 2-stage approach (initial subtotal colectomy with end ileostomy followed by completion proctectomy with IPAA and 
